Please login to the form below

Not currently logged in
Email:
Password:

lipegfilgrastim

This page shows the latest lipegfilgrastim news and features for those working in and with pharma, biotech and healthcare.

Teva withdraws US filing for cancer biologic

Teva withdraws US filing for cancer biologic

There was better news for Teva's G-CSF portfolio however after it launched its long-acting G-CSF product Lonquex (lipegfilgrastim) on November 4 in Germany, the first EU market

Latest news

  • Neulasta rival from Teva cleared in EU Neulasta rival from Teva cleared in EU

    Lonquex (lipegfilgrastim) has been approved to reduce the duration of neutropaenia (low white blood cell counts) and febrile neutropaenia in patients undergoing cytotoxic chemotherapy for cancer, and is given as a ... which like lipegfilgrastim is

  • EMA backs Pomalidomide Celgene in multiple myeloma EMA backs Pomalidomide Celgene in multiple myeloma

    Elsewhere, there were further recommendations for Teva's (Lonquex) lipegfilgrastim, which was recommended for the reduction in white blood cells of cancer patients on chemotherapy; Bavarian Nordic's smallpox vaccine Imnavex;

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics